News
Dec 18
2009
Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
Dec 18
2009
Oct 13
2009
LensAR Inc. to Present Data from Laser Cataract Surgery Clinical Trial at the Annual Meeting of the American Academy of Ophthalmology
Oct 13
2009
Winter Park, FL, October 13, 2009 – LensAR, Inc., a leading developer of next generation laser technology for cataract surgery and other ocular applications, today announced that data from a recently completed clinical trial of the LensAR Laser System will be presented at the upcoming 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and Pan-American Academy of Ophthalmology (PAAO). The meeting will be held October 23 – 27, 2009 in San Francisco, CA.
READ MORE about LensAR Inc. to Present Data from Laser Cataract Surgery Clinical Trial at the Annual Meeting of the American Academy of Ophthalmology
Oct 8
2009
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
Oct 8
2009
Oct 7
2009
TransEnterix Secures $55 Million in Financing
Oct 7
2009
Sep 25
2009
Allos Therapeutics' FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Sep 25
2009
Sep 16
2009
Sirion Therapeutics Announces FDA Approval of Zirgan™ (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis
Sep 16
2009
Sep 9
2009
VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
Sep 9
2009
MOUNTAIN VIEW, Calif., Sept 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of Qnexa(TM), an investigational drug, in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes.
READ MORE about VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
Jun 17
2009
Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules
Jun 17
2009
May 26
2009
MAP Pharmaceuticals Phase 3 Trial of LEVADEX™ Migraine Product Candidate Meets All Four Primary Endpoints
May 26
2009
May 11
2009
SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.
May 11
2009
CARLSBAD, CALIF. – May 11, 2009 – SkinMedica, Inc. today announced that it has entered into a co-promotion agreement with Allergan for ACZONE® (dapsone) Gel 5%, a first-in-class topical treatment for acne vulgaris. Representing the first new molecule in a decade approved by the FDA for the topical treatment of acne in patients 12 years of age and older, ACZONE® Gel 5% combines dapsone in a Solvent Microparticulate™gel, enabling dapsone to be applied topically in a well-tolerated formulation to provide patients with a convenient and effective therapy. Under the agreement, SkinMedica will exclusively promote ACZONE® Gel 5% to pediatricians in the United States through its existing sales force.
READ MORE about SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.